Elizabeth A. Conner, Ph.D.
Dr. Conner manages the CCR Genomics Core, which provides NCI intramural investigators with a range of genomics technologies, available either as services delivered by the Core or as walk-up access to specific instrumentation and technologies.
For more information, visit the CCR Genomics Core.
The CCR Genomics Core (Building 37) is affiliated with the Genetics Branch. This core, under the supervision of Dr. Liz Conner, supports the NCI-CCR scientific research community by providing training, instrumentation, and expertise for a range of genomics technologies.
- Sanger Sequencing
- Nanostring Digital Gene Expression Analysis
- Next-Generation Sequencing on Illumina Mi Seq & NextSeq500
- Fluidigm C1 Single Cell Autoprep System for Genomic Analysis of Single Cells
- Bio-Rad QX200 Droplet Digital PCR System
For more information or to access services, visit the CCR Genomics Core.
Selected Recent Publications
Curcumin effectively inhibits oncogenic NF-kB signaling and restrains stemness features in liver cancer.J. Hepatol. [Epub ahead of print - Apr. 30], 2015. [ Journal Article ]
The transcription factor GTF2IRD1 regulates the topology and function of photoreceptors by modulating photoreceptor gene expression across the retina.J Neurosci. 34: 15356-68, 2014. [ Journal Article ]
- Cancer Res. 74: 5903-13, 2014. [ Journal Article ]
- Cancer Res. 74: 4752-61, 2014. [ Journal Article ]
- Genes Dev. 27: 1706-17, 2013. [ Journal Article ]
Dr. Conner received her B.A. from McDaniel College (formerly Western Maryland College) in 1987, graduating Cum Laude in biology. She received her Ph.D. in 1993 from the Program in Toxicology at the University of Maryland Medical School in Baltimore, Maryland where she studied biochemical mechanisms of cell injury from toxic metals and the regulatory roles of high-affinity metal binding proteins in mediating cell injury. Her career at NIH began in 1993 as a postdoctoral fellow, in the Laboratory of Experimental Carcinogenesis (LEC) at the NCI under Dr. Snorri Thorgeirsson. Her research focused first on gene amplification as an indicator of genomic instability. Later, she became interested in the role of growth factor signaling in liver tumor development and generated a transgenic mouse model that overexpresses E2F1 and c-myc in the liver. In 1999 Dr. Conner was put in charge of the LEC transgenic mouse facility, generating numerous transgenic and knock-out mouse lines that reproducibly developed liver cancer. Dr. Conner served as the technical laboratory manager for the LEC from 2002 to 2014 where she continued her research on the molecular pathogenesis of human liver cancer. In 2014, Dr. Conner joined the Genetics Branch as the manager of the CCR Genomics Core.